PEGS Korea The Essential Protein Engineering Summit

PEGS Korea The Essential Protein Engineering Summit
SEPTEMBER 1-3,2015 | JW MARRIOTT SEOUL
SEOUL,SOUTH KOREA

PEGS is Cambridge Healthtech Institute (CHI)’s flagship biologics meeting, and is widely considered the industry’s leading event on protein and antibody engineering. Its successful accolades include an annual attendance of over 1800 participants at the PEGS Summit in Boston, a record attendance of over 500 attendees at PEGS Europe last year, a successful launch of PEGS China in 2014, and now, we proudly announce PEGS Korea.

This 3 day inaugural event will bring together an international faculty of scientists, professors and managers from leading universities, research laboratories and biopharmaceutical companies to share practical applications and case examples in protein and antibody engineering and novel biotherapeutics development.

PROGRAMS

Protein & Antibody Engineering
September 1-2, 2015| JW Marriott Seoul | Seoul, South Korea

The advancements in science and technology have opened the door to innovative approaches in protein and antibody engineering, enabling new generations of protein and antibody formats to increasingly make their way from bench to clinic. Today’s protein scientists are focused on understanding MOAs and structure-function relationships, identifying and validating novel targets, developing antibodies against challenging targets, delivering drugs to specific targets, designing novel formats and next generation products with increased potency, specificity and increased resistance to aggregation and immunogenicity.

At the Protein & Antibody Engineering conference, our goal is to bring together international and domestic scientists to share and discuss their efforts in the above areas as well as facilitate collaborations toward this new frontier of biotherapeutic discovery and development.

Next-Generation Antibody Therapeutics
September 2-3, 2015| JW Marriott Seoul | Seoul, South Korea

Thanks to the rapid growth in the field of immunotherapy, and advancements in bispecifics and ADCs, we are seeing an exciting flurry of activities in the clinic. From engineered T-cells to novel ADC payloads, from activating the immune system to employing combination approaches, these novel therapeutics are making headlines as the future best-in-class drugs.

At the Next Generation Antibody Therapeutics conference, we will focus on some of the leading biotherapeutics in preclinical and clinical development, and will explore their MOAs, targets, preclinical data, proof-of-concept studies, in vitro and in vivo correlation, early clinical results as well as the safety and efficacy profiles.

KEYNOTE SPEAKERS
Andrew Bradbury , M.B.B.S., Ph.D., Biosciences Division, Los Alamos National Laboratory
Gregory P. Adams, Ph.D., Director of Biological Research and Therapeutics, Fox Chase Cancer Center

SPEAKERS
Jeiwook Chae, Ph.D., Vice President, Biology, Legochem
Ho Cho, Ph.D., Vice President, Biotherapeutics, Celgene Therapeutics
Stefan Duebel, Ph.D., Professor and Managing Director, Institute of Biochemistry, Biotechnology and Bioinformatics, Technische Universitat Braunschweig, Germany
Mariangela Figini, Ph.D., Head, Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori Milano
William (Jonny) Finlay, Ph.D., Director, Protein Discovery & Optimization, Global Biotherapeutics Technologies, Pfizer Ireland
Tariq Ghayur, Ph.D., Senior Research Fellow & Principal Scientist, Abbvie Bioresearch Center
Sang Taek Jung, Ph.D., Professor, Department of Bio and Nano Chemistry, Kookmin University
Syd Johnson, Ph.D., Vice President, Antibody Engineering, MacroGenics, Inc.
Stacy Kenyon, Ph.D., Scientist, Bioscience Development Initiative, Malvern Instruments Ltd.
Kyu-Tae Kim, Ph.D., Director, ADDs, AbClon, Inc.
Sunghoon Kim, Ph.D., Professor and Director, Medicinal Bioconvergence Research Center, Molecular Medicine and Biopharmaceutical Sciences, Seoul National University
Yong-Sung Kim, Ph.D., Professor, Department of Molecular Science & Technology, Ajou University, Korea
Manfred Konrad, Ph.D., Professor, Research Director, Enzyme Biochemistry, Max Planck Institute for Biophysical Chemistry
Byoung-Chul Lee, Ph.D., Scientist, Protein Chemistry, Genentech, Inc.
Gwanghee Lee, Ph.D., Cancer Project Leader, Therapeutic Strategic Unit, Asia Pacific R&D, Sanofi
Sukmook Lee, Ph.D., Principal Investigator, Research Center, Scripps Korea Antibody Institute
Jing Li, M.D., Ph.D., MBA, Vice President, Biologics Discovery, WuXi AppTec
John McCafferty, Ph.D., CEO, IONTAS
Andreas Pahl, Ph.D., CEO, Heidelberg Pharma
Soon Jae Park, Ph.D., CEO, Alteogen, Inc.
Sofie Pattijn, CTO, ImmunXperts
Sai Reddy, Ph.D., Assistant Professor, Biomolecular Engineering, Department of Biosystems, ETH Zurich
Yoram Reiter, Ph.D., Professor & Head, Laboratory of Molecular Immunology, Technion-Israel Institute of Technology
Aaron Sato, Ph.D., Vice President, Research, Sutro Biopharma, Inc.
Michael Schopperle, Ph.D., CEO, CureMeta
Hyunbo Shim, Ph.D., Assistant Professor, Department of Bioinspired Science, Ewha Womans University
Mohit Trikha, Ph.D., CSO, Executive Vice President and Head, R&D, Triphase Accelerator
Cheng-I Wang, Ph.D., Principal Investigator, Therapeutic Antibody Engineering, Singapore Immunology Network
Jonghwa Won, Ph.D., Senior Research Director, Oncology Team, Mogam Biotechnology Institute
Jin-San Yoo, Ph.D., CEO, President & Founder, PharmAbcine
Weon-Kyoo You, Principal Research Scientist, Biologics Unit, Hanwha Chemical

SPONSORSHIP OPPORTUNITIES
Agenda & Breakfast Presentations
Showcase your solutions to a guaranteed, highly-targeted audience. Package includes a 15- or 30-minute podium presentation within the scientific agenda, exhibit space, branding, registrations and use of the mailing list.

Invitation-Only VIP Dinner/Hospitality Suite
Select your top prospects from the conference pre-registration list for an evening of networking at the hotel, or at a choice local venue. CHI will extend invitations, conduct follow-up and confirm attendees.

Other opportunities include:
•Conference Tote Bags
•Badge Lanyards
•Notebooks
•Literature Distribution
•Exhibit Hall Reception
•Networking Luncheon

Looking for additional ways to drive leads to your sales team?
CHI’s Lead Generation Programs will help you obtain more targeted, quality leads throughout the year. We will mine our database of 800,000+ life science professionals to your specific needs. We guarantee a minimum of 100 leads per program! Opportunities include:

•Whitepapers
•Web Symposia
•Custom Market Research Surveys
•Podcasts

For more information, contact:
Companies A-K:
Jason Gerardi
Manager, Business Development
T: 781-972-5452
E: jgerardi@healthtech.com  

Companies L-Z:
Carol Dinerstein
Director, Business Development
T: 781-972-5471
E: dinerstein@healthtech.com